

Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A4FCB16E474EEN.html>

Date: May 2022

Pages: 68

Price: US\$ 2,000.00 (Single User License)

ID: A4FCB16E474EEN

Abstracts

Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Actinic (Solar) Keratosis - Drugs In Development, 2022, provides an overview of the Actinic (Solar) Keratosis (Dermatology) pipeline landscape.

An actinic keratosis, also known as a solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck or any other areas of the body frequently exposed to the sun. The signs and symptoms of an actinic keratosis include a hard, wart-like surface, patch or bump on the top layer of skin, itching or burning in the affected area and color as varied as pink, red or brown, or flesh-colored. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, and blue or light-colored eyes and a weak immune system as a result of chemotherapy, chronic leukemia, AIDS or organ transplant medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Actinic (Solar) Keratosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action

(MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Actinic (Solar) Keratosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 1, 1, 6, 2, 1, 7 and 2 respectively.

Actinic (Solar) Keratosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Actinic (Solar) Keratosis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Actinic (Solar) Keratosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Actinic (Solar) Keratosis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Actinic (Solar) Keratosis - Overview

Actinic (Solar) Keratosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Actinic (Solar) Keratosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development

Actinic (Solar) Keratosis - Drug Profiles

Actinic (Solar) Keratosis - Dormant Projects

Actinic (Solar) Keratosis - Discontinued Products

Actinic (Solar) Keratosis - Product Development Milestones

Featured News & Press Releases

Feb 18, 2022: Jupiter Wellness completes enrollment in double-blind placebo-controlled clinical trial of JW-200 for the treatment of actinic keratosis

Oct 14, 2021: Indicative announcement aminolevulinic acid hydrochloride topical powder received the acceptance notice for the investigational new drug application

Sep 27, 2021: Almirall launches Klisyri (Tirbanibulin) for the treatment of actinic keratosis in Europe

Sep 20, 2021: Vidac Pharma announces wider spectrum authorization of its CTCL phase 2 clinical trial

Jul 19, 2021: Almirall receives European Commission approval of Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis

May 21, 2021: Almirall receives positive CHMP opinion for Klisyri (tirbanibulin), an innovative topical treatment for actinic keratosis

Feb 18, 2021: Almirall U.S. launches Klisyri (tirbanibulin), a new, innovative topical treatment for actinic keratosis

Feb 18, 2021: Athenex announces U.S. launch of Klisyri and licensing of additional territories for tirbanibulin

Feb 11, 2021: Athenex announces New England Journal of Medicine publication of phase III data on the efficacy and safety of Klisyri (tirbanibulin)

Dec 15, 2020: Almirall announces FDA approval of Klisyri (tirbanibulin), a new

innovative topical treatment for actinic keratosis

Mar 09, 2020: Athenex announces FDA acceptance for filing of U.S. NDA for tirbanibulin ointment in actinic keratosis

Mar 02, 2020: Athenex's partner Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for tirbanibulin ointment in actinic keratosis

Oct 28, 2019: Athenex announces progress update from partner Almirall on Tirbanibulin Ointment

Mar 04, 2019: Athenex announces positive topline results from two phase III studies of KX2-391 ointment 1% featured in late breaker program at the 2019 American Academy of Dermatology Annual Meeting

Feb 25, 2019: Athenex to host conference call with key opinion leader following oral presentation of phase III results of KX2-391 ointment in the treatment of actinic keratosis at the American Academy of Dermatology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Actinic (Solar) Keratosis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Actinic (Solar) Keratosis - Pipeline by Athenex Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Claradele Pharmaceuticals Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Coegin Pharma AS, 2022
Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., 2022
Actinic (Solar) Keratosis - Pipeline by Ingenew Pharmaceuticals Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Invion Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Jupiter Wellness Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma SL, 2022
Actinic (Solar) Keratosis - Pipeline by MedC Biopharma Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by MediWound Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Nanology LLC, 2022
Actinic (Solar) Keratosis - Pipeline by Neonc Technologies Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Oncology Research International Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Ponce Therapeutics Inc, 2022
Actinic (Solar) Keratosis - Pipeline by Provectus Biopharmaceuticals Inc, 2022
Actinic (Solar) Keratosis - Pipeline by RepoCeuticals ApS, 2022
Actinic (Solar) Keratosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Singh Biotechnology LLC, 2022
Actinic (Solar) Keratosis - Pipeline by Sol-Gel Technologies Ltd, 2022
Actinic (Solar) Keratosis - Pipeline by Vidac Pharma, 2022
Actinic (Solar) Keratosis - Dormant Projects, 2022
Actinic (Solar) Keratosis - Dormant Projects, 2022 (Contd..1)
Actinic (Solar) Keratosis - Dormant Projects, 2022 (Contd..2)
Actinic (Solar) Keratosis - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Actinic (Solar) Keratosis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A4FCB16E474EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4FCB16E474EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

